Connection

William Creasman to Humans

Back to Details
This is a "connection" page, showing publications William Creasman has written about Humans.
William Creasman
Connection Strength
0.823
Humans
  1. Why do we continue to overtreat stage Ia?carcinoma of the cervix? Am J Obstet Gynecol. 2017 10; 217(4):413-417.
    View in: PubMed
    Score: 0.022
  2. Surgical-pathological findings in type 1 and 2 endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study on GOG-210 protocol. Gynecol Oncol. 2017 06; 145(3):519-525.
    View in: PubMed
    Score: 0.022
  3. Lymphovascular space invasion in uterine corpus cancer: What is its prognostic significance in the absence of lymph node metastases? Gynecol Oncol. 2016 08; 142(2):278-82.
    View in: PubMed
    Score: 0.021
  4. Treating Locally Advanced Cervical Cancer With Concurrent Chemoradiation Without Brachytherapy in Low-resource Countries. Am J Clin Oncol. 2016 Feb; 39(1):92-7.
    View in: PubMed
    Score: 0.020
  5. What is the significance of gynecologic symptoms in the participants in the NSABP study? Am J Obstet Gynecol. 2011 Dec; 205(6):511-2.
    View in: PubMed
    Score: 0.015
  6. The current status of lymphadenectomy in the management of endometrial cancer. Womens Health (Lond). 2011 Jan; 7(1):33-5.
    View in: PubMed
    Score: 0.014
  7. Hormone replacement and breast cancer risk: reconsidering the data. Oncology (Williston Park). 2009 Nov 15; 23(12):1099-100; author reply 1100, 1102.
    View in: PubMed
    Score: 0.013
  8. ASTEC lymphadenectomy and radiation therapy studies: are conclusions valid? Gynecol Oncol. 2010 Mar; 116(3):293-4.
    View in: PubMed
    Score: 0.013
  9. How valid are current cervical cancer prognostic factors that are used to recommend adjunctive radiation therapy after radical surgery? Am J Obstet Gynecol. 2009 Sep; 201(3):260.e1-3.
    View in: PubMed
    Score: 0.013
  10. Revised FIGO staging for carcinoma of the endometrium. Int J Gynaecol Obstet. 2009 May; 105(2):109.
    View in: PubMed
    Score: 0.013
  11. Controversies surrounding lymphadenectomy and postoperative radiotherapy in the treatment of carcinoma of the endometrium. Future Oncol. 2008 Jun; 4(3):379-87.
    View in: PubMed
    Score: 0.012
  12. History of the FIGO cancer staging system. Int J Gynaecol Obstet. 2008 May; 101(2):205-10.
    View in: PubMed
    Score: 0.012
  13. Carcinoma of the corpus uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S105-43.
    View in: PubMed
    Score: 0.011
  14. Serum vascular endothelial growth factor C (VEGF-C) as a specific biomarker for advanced cervical cancer: Relationship to insulin-like growth factor II (IGF-II), IGF binding protein 3 (IGF-BP3) and VEGF-A [corrected]. Gynecol Oncol. 2005 Sep; 98(3):467-83.
    View in: PubMed
    Score: 0.010
  15. Hormone replacement therapy after cancers. Curr Opin Oncol. 2005 Sep; 17(5):493-9.
    View in: PubMed
    Score: 0.010
  16. Breast cancer: the role of hormone therapy. Semin Reprod Med. 2005 May; 23(2):167-71.
    View in: PubMed
    Score: 0.010
  17. Vaginal cancers. Curr Opin Obstet Gynecol. 2005 Feb; 17(1):71-6.
    View in: PubMed
    Score: 0.009
  18. Prognosis of papillary serous, clear cell, and grade 3 stage I carcinoma of the endometrium. Gynecol Oncol. 2004 Dec; 95(3):593-6.
    View in: PubMed
    Score: 0.009
  19. Is lymph vascular space involvement an independent prognostic factor in early cervical cancer? Gynecol Oncol. 2004 Feb; 92(2):525-9.
    View in: PubMed
    Score: 0.009
  20. Circulating levels of insulin-like growth factor-II and IGF-binding protein 3 in cervical cancer. Gynecol Oncol. 2003 Dec; 91(3):486-93.
    View in: PubMed
    Score: 0.009
  21. Carcinoma of the vulva. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:7-26.
    View in: PubMed
    Score: 0.009
  22. Carcinoma of the vagina. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:27-39.
    View in: PubMed
    Score: 0.009
  23. Carcinoma of the corpus uteri. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:79-118.
    View in: PubMed
    Score: 0.009
  24. Gestational trophoblastic diseases. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:167-74.
    View in: PubMed
    Score: 0.009
  25. WHI: Now that the dust has settled: a commentary. Am J Obstet Gynecol. 2003 Sep; 189(3):621-6.
    View in: PubMed
    Score: 0.009
  26. Expression of cyclooxygenase-2 in cervical, endometrial, and ovarian malignancies. Am J Obstet Gynecol. 2003 May; 188(5):1174-6.
    View in: PubMed
    Score: 0.008
  27. Estrogen and cancer. Gynecol Oncol. 2002 Jul; 86(1):1-9.
    View in: PubMed
    Score: 0.008
  28. Phase II trial of pyrazoloacridine in recurrent platinum-sensitive ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 2002 Jan; 84(1):32-5.
    View in: PubMed
    Score: 0.008
  29. Evaluation of recombinant human interleukin-12 in patients with recurrent or refractory ovarian cancer: a gynecologic oncology group study. Gynecol Oncol. 2001 Jul; 82(1):7-10.
    View in: PubMed
    Score: 0.007
  30. The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women. Gynecol Oncol. 2021 03; 160(3):660-668.
    View in: PubMed
    Score: 0.007
  31. Clinical evaluation of atypical glandular cells of undetermined significance. Am J Obstet Gynecol. 2001 Jan; 184(2):64-9.
    View in: PubMed
    Score: 0.007
  32. Surgical training in gynecologic oncology: Past, present, future. Gynecol Oncol. 2020 07; 158(1):188-193.
    View in: PubMed
    Score: 0.007
  33. Stage IA cancer of the cervix: finally some resolution of definition and treatment? Gynecol Oncol. 1999 Aug; 74(2):163-4.
    View in: PubMed
    Score: 0.006
  34. Significance of true surgical pathologic staging: a Gynecologic Oncology Group Study. Am J Obstet Gynecol. 1999 Jul; 181(1):31-4.
    View in: PubMed
    Score: 0.006
  35. A survey of hospital management practices for vulvar melanoma. J Am Coll Surg. 1999 Jun; 188(6):670-5.
    View in: PubMed
    Score: 0.006
  36. An experience with estrogen replacement therapy in breast cancer survivors. Int J Fertil Womens Med. 1999 Jun-Aug; 44(4):186-92.
    View in: PubMed
    Score: 0.006
  37. HRT and women who have had breast or endometrial cancer. J Epidemiol Biostat. 1999; 4(3):217-20; discussion 221-5.
    View in: PubMed
    Score: 0.006
  38. Is there an association between hormone replacement therapy and breast cancer? J Womens Health. 1998 Dec; 7(10):1231-46.
    View in: PubMed
    Score: 0.006
  39. The National Cancer Data Base report on cancer of the vagina. Cancer. 1998 Sep 01; 83(5):1033-40.
    View in: PubMed
    Score: 0.006
  40. Receipt of adjuvant endometrial cancer treatment according to race: an?NRG Oncology/Gynecologic Oncology Group 210 Study. Am J Obstet Gynecol. 2018 11; 219(5):459.e1-459.e11.
    View in: PubMed
    Score: 0.006
  41. Early invasive carcinoma of the cervix (3 to 5 mm invasion): risk factors and prognosis. A Gynecologic Oncology Group study. Am J Obstet Gynecol. 1998 Jan; 178(1 Pt 1):62-5.
    View in: PubMed
    Score: 0.006
  42. An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer. Gynecol Oncol. 2018 01; 148(1):174-180.
    View in: PubMed
    Score: 0.006
  43. Endometrial carcinoma recurrence according to race and ethnicity: An NRG Oncology/Gynecologic Oncology Group 210 Study. Int J Cancer. 2018 03 15; 142(6):1102-1115.
    View in: PubMed
    Score: 0.006
  44. Dysregulation of miR-181c expression influences recurrence of endometrial endometrioid adenocarcinoma by modulating NOTCH2 expression: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2017 12; 147(3):648-653.
    View in: PubMed
    Score: 0.006
  45. The National Cancer Data Base report on early stage invasive vulvar carcinoma. The American College of Surgeons Commission on Cancer and the American Cancer Society. Cancer. 1997 Aug 01; 80(3):505-13.
    View in: PubMed
    Score: 0.006
  46. Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: a Gynecologic Oncology Group Study. Gynecol Oncol. 1997 Aug; 66(2):171-8.
    View in: PubMed
    Score: 0.006
  47. Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (Gynecologic Oncology Group 240). Lancet. 2017 Oct 07; 390(10103):1654-1663.
    View in: PubMed
    Score: 0.006
  48. Nonsteroidal Anti-inflammatory Drugs and Endometrial Carcinoma Mortality and Recurrence. J Natl Cancer Inst. 2017 03 01; 109(3):1-10.
    View in: PubMed
    Score: 0.005
  49. Endometrial cancer: incidence, prognostic factors, diagnosis, and treatment. Semin Oncol. 1997 Feb; 24(1 Suppl 1):S1-140-S1-50.
    View in: PubMed
    Score: 0.005
  50. Synuclein-? in uterine serous carcinoma impacts survival: An NRG Oncology/Gynecologic Oncology Group study. Cancer. 2017 04 01; 123(7):1144-1155.
    View in: PubMed
    Score: 0.005
  51. Disease extent at secondary cytoreductive surgery is predictive of progression-free and overall survival in advanced stage ovarian cancer: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Dec; 143(3):511-515.
    View in: PubMed
    Score: 0.005
  52. The role of racial genetic admixture with endometrial cancer outcomes: An NRG Oncology/Gynecologic Oncology Group study. Gynecol Oncol. 2016 Feb; 140(2):264-9.
    View in: PubMed
    Score: 0.005
  53. Replacement therapy for breast cancer survivors. A pilot study. Cancer. 1995 Nov 15; 76(10 Suppl):2075-8.
    View in: PubMed
    Score: 0.005
  54. Associations between etiologic factors and mortality after endometrial cancer diagnosis: the NRG Oncology/Gynecologic Oncology Group 210 trial. Gynecol Oncol. 2015 Oct; 139(1):70-6.
    View in: PubMed
    Score: 0.005
  55. New gynecologic cancer staging. Gynecol Oncol. 1995 Aug; 58(2):157-8.
    View in: PubMed
    Score: 0.005
  56. Relationships of Tubal Ligation to Endometrial Carcinoma Stage and Mortality in the NRG Oncology/ Gynecologic Oncology Group 210 Trial. J Natl Cancer Inst. 2015 Sep; 107(9).
    View in: PubMed
    Score: 0.005
  57. Neoadjuvant chemotherapy with vincristine and cisplatin followed by radical hysterectomy and pelvic lymphadenectomy for FIGO stage IB bulky cervical cancer: a Gynecologic Oncology Group pilot study. Gynecol Oncol. 1995 Jun; 57(3):412-6.
    View in: PubMed
    Score: 0.005
  58. Ovarian cancer screening. J Clin Oncol. 1995 Mar; 13(3):783-93.
    View in: PubMed
    Score: 0.005
  59. Second-look laparotomy in ovarian cancer. Gynecol Oncol. 1994 Dec; 55(3 Pt 2):S122-7.
    View in: PubMed
    Score: 0.005
  60. Adverse effect of electrosurgical loop excision on assignment of FIGO stage in cervical cancer: report of two cases. Gynecol Oncol. 1994 Nov; 55(2):313-7.
    View in: PubMed
    Score: 0.005
  61. Teaching gynecologic oncology in Low resource settings: a collaboration of health volunteers overseas and the society of gynecologic oncology. Gynecol Oncol. 2014 Dec; 135(3):580-2.
    View in: PubMed
    Score: 0.005
  62. Limited disease: role of surgery. Semin Oncol. 1994 Feb; 21(1):79-83.
    View in: PubMed
    Score: 0.004
  63. Hydroxyurea versus misonidazole with radiation in cervical carcinoma: long-term follow-up of a Gynecologic Oncology Group trial. J Clin Oncol. 1993 Aug; 11(8):1523-8.
    View in: PubMed
    Score: 0.004
  64. Transcriptional suppression, DNA methylation, and histone deacetylation of the regulator of G-protein signaling 10 (RGS10) gene in ovarian cancer cells. PLoS One. 2013; 8(3):e60185.
    View in: PubMed
    Score: 0.004
  65. Etiologic heterogeneity in endometrial cancer: evidence from a Gynecologic Oncology Group trial. Gynecol Oncol. 2013 May; 129(2):277-84.
    View in: PubMed
    Score: 0.004
  66. Prognostic significance of hormone receptors in endometrial cancer. Cancer. 1993 Feb 15; 71(4 Suppl):1467-70.
    View in: PubMed
    Score: 0.004
  67. Adenocarcinoma of the uterine corpus. Curr Opin Obstet Gynecol. 1993 Feb; 5(1):80-3.
    View in: PubMed
    Score: 0.004
  68. Revision in classification by International Federation of Gynecology and Obstetrics. Am J Obstet Gynecol. 1992 Sep; 167(3):857-8.
    View in: PubMed
    Score: 0.004
  69. Recommendations regarding estrogen replacement therapy after treatment of endometrial cancer. Oncology (Williston Park). 1992 Jul; 6(7):23-6; discussion 26, 28.
    View in: PubMed
    Score: 0.004
  70. Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. Obstet Gynecol. 1992 Apr; 79(4):490-7.
    View in: PubMed
    Score: 0.004
  71. A case of parametrial lymph node involvement in stage IA2 squamous cell carcinoma of the cervix treated with radical hysterectomy and a review of the literature: a case report. J Low Genit Tract Dis. 2012 Apr; 16(2):145-8.
    View in: PubMed
    Score: 0.004
  72. Epithelial ovarian tumors of low malignant potential. Obstet Gynecol. 1991 Dec; 78(6):1027-32.
    View in: PubMed
    Score: 0.004
  73. Responsiveness of patients with advanced ovarian carcinoma to tamoxifen. A Gynecologic Oncology Group study of second-line therapy in 105 patients. Cancer. 1991 Jul 15; 68(2):269-71.
    View in: PubMed
    Score: 0.004
  74. Estrogen replacement therapy: is previously treated cancer a contraindication? Obstet Gynecol. 1991 Feb; 77(2):308-12.
    View in: PubMed
    Score: 0.004
  75. Reproductive hormone levels in gynecologic oncology patients undergoing surgical castration after spontaneous menopause. Gynecol Oncol. 1991 Jan; 40(1):42-5.
    View in: PubMed
    Score: 0.004
  76. Is laser surgery superior to cryosurgery for the treatment of high grade CIN? Con. J Gynecol Surg. 1991; 7(1):57-9.
    View in: PubMed
    Score: 0.004
  77. A randomized trial of cyclophosphamide, doxorubicin, and cisplatin with or without bacillus Calmette-Guerin in patients with suboptimal stage III and IV ovarian cancer: a Gynecologic Oncology Group study. Gynecol Oncol. 1990 Dec; 39(3):239-43.
    View in: PubMed
    Score: 0.004
  78. Adjuvant radiotherapy following radical hysterectomy for patients with stage IB and IIA cervical cancer. Gynecol Oncol. 1990 Jun; 37(3):390-5.
    View in: PubMed
    Score: 0.003
  79. New gynecologic cancer staging. Obstet Gynecol. 1990 Feb; 75(2):287-8.
    View in: PubMed
    Score: 0.003
  80. Recent advances in endometrial cancer. Semin Surg Oncol. 1990; 6(6):339-42.
    View in: PubMed
    Score: 0.003
  81. Second-look laparotomy in the patient with minimal residual stage III ovarian cancer (a Gynecologic Oncology Group Study). Gynecol Oncol. 1989 Dec; 35(3):378-82.
    View in: PubMed
    Score: 0.003
  82. A randomized comparative trial of carboplatin and iproplatin in advanced squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group study. J Clin Oncol. 1989 Oct; 7(10):1462-8.
    View in: PubMed
    Score: 0.003
  83. How good (or bad) is the Pap smear? J S C Med Assoc. 1989 Oct; 85(10):459-62.
    View in: PubMed
    Score: 0.003
  84. Prognostic factors in relation to second-look laparotomy in ovarian cancer. Baillieres Clin Obstet Gynaecol. 1989 Mar; 3(1):183-90.
    View in: PubMed
    Score: 0.003
  85. The role of radiotherapy in the management of resected uterine papillary serous and clear cell carcinoma. Eur J Obstet Gynecol Reprod Biol. 2008 Dec; 141(2):163-8.
    View in: PubMed
    Score: 0.003
  86. A randomized trial of hydroxyurea versus misonidazole adjunct to radiation therapy in carcinoma of the cervix. A preliminary report of a Gynecologic Oncology Group study. Am J Obstet Gynecol. 1988 Jul; 159(1):87-94.
    View in: PubMed
    Score: 0.003
  87. Combined adverse effect of African American race and deep stromal invasion on survival following radical hysterectomy for cervical cancer. Am J Obstet Gynecol. 2008 Aug; 199(2):196.e1-7.
    View in: PubMed
    Score: 0.003
  88. Percutaneous nephrostomy in gynecologic oncology patients. Am J Obstet Gynecol. 1988 May; 158(5):1126-31.
    View in: PubMed
    Score: 0.003
  89. Absorbable synthetic mesh (910-polyglactin) intestinal sling to reduce radiation-induced small bowel injury in patients with pelvic malignancies. Gynecol Oncol. 1988 Mar; 29(3):283-9.
    View in: PubMed
    Score: 0.003
  90. Absorbable synthetic mesh (polyglactin 910) for the formation of a pelvic "lid" after radical pelvic resection. Am J Obstet Gynecol. 1988 Jan; 158(1):158-61.
    View in: PubMed
    Score: 0.003
  91. Intestinal obstruction in patients with ovarian cancer. Variables associated with surgical complications and survival. Arch Surg. 1988 Jan; 123(1):42-5.
    View in: PubMed
    Score: 0.003
  92. Surgical pathologic spread patterns of endometrial cancer. A Gynecologic Oncology Group Study. Cancer. 1987 Oct 15; 60(8 Suppl):2035-41.
    View in: PubMed
    Score: 0.003
  93. Uterine leiomyomas with retroperitoneal lymph node involvement. South Med J. 1987 Oct; 80(10):1320-2.
    View in: PubMed
    Score: 0.003
  94. Treatment of ("bulky") stage IB cervical cancer with or without neoadjuvant vincristine and cisplatin prior to radical hysterectomy and pelvic/para-aortic lymphadenectomy: a phase III trial of the gynecologic oncology group. Gynecol Oncol. 2007 Aug; 106(2):362-9.
    View in: PubMed
    Score: 0.003
  95. Intraperitoneal chromic phosphate P 32 as salvage therapy for persistent carcinoma of the ovary after surgical restaging. Am J Obstet Gynecol. 1987 May; 156(5):1153-8.
    View in: PubMed
    Score: 0.003
  96. Long-term effects on bladder function following radical hysterectomy with and without postoperative radiation. Gynecol Oncol. 1987 Feb; 26(2):160-8.
    View in: PubMed
    Score: 0.003
  97. Papanicolaou smear history of patients developing cervical cancer: an assessment of screening protocols. Obstet Gynecol. 1987 Feb; 69(2):151-5.
    View in: PubMed
    Score: 0.003
  98. Surgical management of intestinal obstruction in ovarian cancer. I. Clinical features, postoperative complications, and survival. Gynecol Oncol. 1987 Jan; 26(1):11-8.
    View in: PubMed
    Score: 0.003
  99. Management of endometrial adenocarcinoma stage I with surgical staging followed by tailored adjuvant radiation therapy. Clin Obstet Gynaecol. 1986 Dec; 13(4):751-65.
    View in: PubMed
    Score: 0.003
  100. Carcinoma of the fallopian tube. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S145-60.
    View in: PubMed
    Score: 0.003
  101. Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S161-92.
    View in: PubMed
    Score: 0.003
  102. Gestational trophoblastic neoplasia. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S193-203.
    View in: PubMed
    Score: 0.003
  103. Carcinoma of the vagina. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S29-42.
    View in: PubMed
    Score: 0.003
  104. Carcinoma of the cervix uteri. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S43-103.
    View in: PubMed
    Score: 0.003
  105. Carcinoma of the vulva. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer. Int J Gynaecol Obstet. 2006 Nov; 95 Suppl 1:S7-27.
    View in: PubMed
    Score: 0.003
  106. Radical hysterectomy as therapy for early carcinoma of the cervix. Am J Obstet Gynecol. 1986 Nov; 155(5):964-9.
    View in: PubMed
    Score: 0.003
  107. Phase II trial of cisplatin in advanced or recurrent cancer of the vagina: a Gynecologic Oncology Group Study. Gynecol Oncol. 1986 Jan; 23(1):101-4.
    View in: PubMed
    Score: 0.003
  108. Superior vena cava syndrome associated with gynecologic malignancy. Gynecol Oncol. 1986 Jan; 23(1):59-64.
    View in: PubMed
    Score: 0.003
  109. Should symptomatic menopausal women be offered hormone therapy? MedGenMed. 2006; 8(2):1 p preceding 35.
    View in: PubMed
    Score: 0.003
  110. Should symptomatic menopausal women be offered hormone therapy? MedGenMed. 2006; 8(3):40.
    View in: PubMed
    Score: 0.003
  111. Assessment of the contemporary management of germ cell malignancies of the ovary. Am J Obstet Gynecol. 1985 Dec 15; 153(8):828-34.
    View in: PubMed
    Score: 0.003
  112. Management of stage IA carcinoma of the cervix. Am J Obstet Gynecol. 1985 Sep 15; 153(2):164-72.
    View in: PubMed
    Score: 0.002
  113. Human lymphoblastoid interferon in the treatment of advanced epithelial ovarian malignancies: a Gynecologic Oncology Group Study. Am J Obstet Gynecol. 1985 Jun 15; 152(4):418-23.
    View in: PubMed
    Score: 0.002
  114. Leiomyosarcoma of the uterus: clinicopathologic study of 21 cases. Gynecol Oncol. 1985 Jun; 21(2):220-7.
    View in: PubMed
    Score: 0.002
  115. Influence of cytoplasmic steroid receptor content on prognosis of early stage endometrial carcinoma. Am J Obstet Gynecol. 1985 Apr 01; 151(7):922-32.
    View in: PubMed
    Score: 0.002
  116. Computed tomography in evaluation of extrapelvic lymphadenopathy in carcinoma of the cervix. Obstet Gynecol. 1985 Jan; 65(1):73-6.
    View in: PubMed
    Score: 0.002
  117. A VP16-213- and cisplatin-containing regimen for treatment of refractory ovarian germ cell malignancies. Am J Obstet Gynecol. 1984 Dec 15; 150(8):927-31.
    View in: PubMed
    Score: 0.002
  118. Complications of low-dose heparin prophylaxis in gynecologic oncology surgery. Obstet Gynecol. 1984 Nov; 64(5):689-94.
    View in: PubMed
    Score: 0.002
  119. Postoperative pelvic vein thrombosis and pulmonary embolism detected by indium 111-labeled platelet imaging: a case report. Am J Obstet Gynecol. 1984 Aug 01; 149(7):796-8.
    View in: PubMed
    Score: 0.002
  120. A phase II study of PALA (NSC 224131) in patients with advanced ovarian carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol. 1984 Jun; 7(3):257-60.
    View in: PubMed
    Score: 0.002
  121. The natural history of postoperative venous thromboemboli in gynecologic oncology: a prospective study of 382 patients. Am J Obstet Gynecol. 1984 Apr 15; 148(8):1051-4.
    View in: PubMed
    Score: 0.002
  122. Vitamin-B12 deficiency following therapy in gynecologic oncology. Gynecol Oncol. 1984 Mar; 17(3):370-4.
    View in: PubMed
    Score: 0.002
  123. The significance of peritoneal cytology in patients with carcinoma of the cervix. Gynecol Oncol. 1984 Feb; 17(2):139-48.
    View in: PubMed
    Score: 0.002
  124. Cryosurgery in the management of cervical intraepithelial neoplasia. Obstet Gynecol. 1984 Feb; 63(2):145-9.
    View in: PubMed
    Score: 0.002
  125. Anticoagulation therapy for venous thromboembolism in patients with gynecologic malignancy. Am J Obstet Gynecol. 1983 Oct 15; 147(4):369-75.
    View in: PubMed
    Score: 0.002
  126. Carcinoma of the cervix uteri. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:41-78.
    View in: PubMed
    Score: 0.002
  127. Carcinoma of the Fallopian tube. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:119-33.
    View in: PubMed
    Score: 0.002
  128. Carcinoma of the ovary. Int J Gynaecol Obstet. 2003 Oct; 83 Suppl 1:135-66.
    View in: PubMed
    Score: 0.002
  129. Cryotherapy in the treatment of cervical intraepithelial neoplasia. Obstet Gynecol. 1983 Sep; 62(3):353-8.
    View in: PubMed
    Score: 0.002
  130. Intracavitary Corynebacterium parvum for treatment of malignant effusions. Gynecol Oncol. 1983 Aug; 16(1):6-14.
    View in: PubMed
    Score: 0.002
  131. Venous thromboembolism prophylaxis in gynecologic oncology: a prospective, controlled trial of low-dose heparin. Am J Obstet Gynecol. 1983 Mar 01; 145(5):606-13.
    View in: PubMed
    Score: 0.002
  132. Thromboembolism complicating surgery for cervical and uterine malignancy: incidence, risk factors, and prophylaxis. Obstet Gynecol. 1983 Jan; 61(1):87-94.
    View in: PubMed
    Score: 0.002
  133. Immune complexes in ovarian cancer. Gynecol Oncol. 1982 Apr; 13(2):203-12.
    View in: PubMed
    Score: 0.002
  134. A trial of prophylactic cefamandole in extended gynecologic surgery. Obstet Gynecol. 1982 Mar; 59(3):309-14.
    View in: PubMed
    Score: 0.002
  135. Significant venous thromboembolism caused by pelvic lymphocysts: diagnosis and management. Gynecol Oncol. 1982 Feb; 13(1):136-43.
    View in: PubMed
    Score: 0.002
  136. Stage I borderline ovarian tumors. Obstet Gynecol. 1982 Jan; 59(1):93-6.
    View in: PubMed
    Score: 0.002
  137. Prognostic significance of peritoneal cytology in patients with endometrial cancer and preliminary data concerning therapy with intraperitoneal radiopharmaceuticals. Am J Obstet Gynecol. 1981 Dec 15; 141(8):921-9.
    View in: PubMed
    Score: 0.002
  138. Ovarian carcinoma: histologic and clinical correlation of cytoplasmic estrogen and progesterone binding. Gynecol Oncol. 1981 Dec; 12(3):319-27.
    View in: PubMed
    Score: 0.002
  139. Radioactive chromic phosphate suspension: studies on distribution, dose absorption, and effective therapeutic radiation in phantoms, dogs, and patients. Gynecol Oncol. 1981 Oct; 12(2 Pt 1):193-218.
    View in: PubMed
    Score: 0.002
  140. Results of outpatient therapy of cervical intraepithelial neoplasia. Gynecol Oncol. 1981 Oct; 12(2 Pt 2):S306-16.
    View in: PubMed
    Score: 0.002
  141. The abnormal Pap smear--what to do next? Cancer. 1981 Jul 15; 48(2 Suppl):515-22.
    View in: PubMed
    Score: 0.002
  142. The role of adjuvant therapy in Stage I ovarian cancer. Am J Obstet Gynecol. 1980 Sep 15; 138(2):139-45.
    View in: PubMed
    Score: 0.002
  143. Cancer of the endometrium. Curr Probl Cancer. 1980 Aug; 5(2):1-33.
    View in: PubMed
    Score: 0.002
  144. Conservative management of cervical intraepithelial neoplasia. Clin Obstet Gynecol. 1980 Mar; 23(1):281-91.
    View in: PubMed
    Score: 0.002
  145. Clinical correlates of estrogen- and progesterone-binding proteins in human endometrial adenocarcinoma. Obstet Gynecol. 1980 Mar; 55(3):363-70.
    View in: PubMed
    Score: 0.002
  146. A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma. Am J Obstet Gynecol. 1979 Nov 01; 135(5):647-50.
    View in: PubMed
    Score: 0.002
  147. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet. 1999 Jun; 65(3):243-9.
    View in: PubMed
    Score: 0.002
  148. Unusual metastasis in carcinoma of the cervix uteri. Surg Gynecol Obstet. 1979 May; 148(5):728-30.
    View in: PubMed
    Score: 0.002
  149. Stage II carcinoma of the endometrium. Int J Radiat Oncol Biol Phys. 1979 Mar; 5(3):323-6.
    View in: PubMed
    Score: 0.002
  150. Chemoimmunotherapy in the management of primary stage III ovarian cancer: a Gynecologic Oncology Group study. Cancer Treat Rep. 1979 Feb; 63(2):319-23.
    View in: PubMed
    Score: 0.002
  151. FIGO staging of gynecologic cancer. 1994-1997 FIGO Committee on Gynecologic Oncology. International Federation of Gynecology and Obstetrics. Int J Gynaecol Obstet. 1999 Jan; 64(1):5-10.
    View in: PubMed
    Score: 0.002
  152. Toxicity manifestations following intravenous Corynebacterium parvum administration to patients with ovarian and cervical carcinoma. Am J Obstet Gynecol. 1978 Nov 01; 132(5):555-60.
    View in: PubMed
    Score: 0.002
  153. Retroperitoneal metastatic spread of ovarian cancer. Gynecol Oncol. 1978 Oct; 6(5):447-50.
    View in: PubMed
    Score: 0.002
  154. A phase II trial of prolonged oral etoposide (VP-16) as second-line therapy for advanced and recurrent endometrial carcinoma: a Gynecologic Oncology Group study. Gynecol Oncol. 1996 Oct; 63(1):101-4.
    View in: PubMed
    Score: 0.001
  155. Adenocarcinoma of the endometrium: its metastatic lymph node potential. A preliminary report. Gynecol Oncol. 1976 Sep; 4(3):239-43.
    View in: PubMed
    Score: 0.001
  156. Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. Gynecol Oncol. 1996 Jul; 62(1):4-6.
    View in: PubMed
    Score: 0.001
  157. Operative management of early invasive epidermoid carcinoma of the vulva. Am J Obstet Gynecol. 1975 Oct 15; 123(4):349-55.
    View in: PubMed
    Score: 0.001
  158. Management of early cervical neoplasia. Clin Obstet Gynecol. 1975 Sep; 18(3):233-45.
    View in: PubMed
    Score: 0.001
  159. Meningeal carcinomatosis secondary to advanced squamous cell carcinoma of the cervix: a case report. Meningeal metastasis of advenced cervical cancer. Gynecol Oncol. 1975 Sep; 3(3):201-4.
    View in: PubMed
    Score: 0.001
  160. Assessment of dose-intensive therapy in suboptimally debulked ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 1995 Jul; 13(7):1589-99.
    View in: PubMed
    Score: 0.001
  161. Paget's disease of the vulva. Gynecol Oncol. 1975 Jun; 3(2):133-48.
    View in: PubMed
    Score: 0.001
  162. Is positive pelvic lymphadenopathy a contraindication to radical surgery in recurrent cervical carcinoma? Gynecol Oncol. 1974 Dec; 2(4):482-5.
    View in: PubMed
    Score: 0.001
  163. The effect of diameter of largest residual disease on survival after primary cytoreductive surgery in patients with suboptimal residual epithelial ovarian carcinoma. Am J Obstet Gynecol. 1994 Apr; 170(4):974-9; discussion 979-80.
    View in: PubMed
    Score: 0.001
  164. Experience with a mass closure technique using continuous looped polyglyconate absorbable suture. J Am Coll Surg. 1994 Feb; 178(2):177-80.
    View in: PubMed
    Score: 0.001
  165. Microinvasive carcinoma of the cervix. Clin Obstet Gynecol. 1973 Jun; 16(2):261-75.
    View in: PubMed
    Score: 0.001
  166. Efficacy of cryosurgical treatment of severe cervical intraepithelial neoplasia. Obstet Gynecol. 1973 Apr; 41(4):501-6.
    View in: PubMed
    Score: 0.001
  167. Prognostic factors in early-stage uterine sarcoma. A Gynecologic Oncology Group study. Cancer. 1993 Feb 15; 71(4 Suppl):1702-9.
    View in: PubMed
    Score: 0.001
  168. Age as a prognostic factor in ovarian carcinoma. The Gynecologic Oncology Group experience. Cancer. 1993 Jan 15; 71(2 Suppl):606-14.
    View in: PubMed
    Score: 0.001
  169. Preoperative evaluation of patients with recurrent carcinoma of the cervix. Gynecol Oncol. 1972 Nov; 1(1):111-8.
    View in: PubMed
    Score: 0.001
  170. Unreliability of urinary cytology in detecting gynecologic malignancy. Cancer. 1972 Jul; 30(1):148-9.
    View in: PubMed
    Score: 0.001
  171. Carcinoma in situ of the cervix. An analysis of 861 patients. Obstet Gynecol. 1972 Mar; 39(3):373-80.
    View in: PubMed
    Score: 0.001
  172. Antepartum pulmonary embolism. Am J Obstet Gynecol. 1972 Feb 15; 112(4):476-86.
    View in: PubMed
    Score: 0.001
  173. Role of the fallopian tube in dissemination of malignant cells in corpus cancer. Cancer. 1972 Feb; 29(2):456-7.
    View in: PubMed
    Score: 0.001
  174. Ovarian metastases in stage IB carcinoma of the cervix: a Gynecologic Oncology Group study. Am J Obstet Gynecol. 1992 Jan; 166(1 Pt 1):50-3.
    View in: PubMed
    Score: 0.001
  175. Coordinate elevation of serum markers in ovarian cancer but not in benign disease. Cancer. 1991 Oct 15; 68(8):1758-63.
    View in: PubMed
    Score: 0.001
  176. The prognostic value of peritoneal cytology in gynecologic malignant disease. Am J Obstet Gynecol. 1971 Jul 15; 110(6):773-81.
    View in: PubMed
    Score: 0.001
  177. Screening in ovarian cancer. Am J Obstet Gynecol. 1991 Jul; 165(1):7-10.
    View in: PubMed
    Score: 0.001
  178. Carcinoma of the ovary associated with pregnancy. Obstet Gynecol. 1971 Jul; 38(1):111-6.
    View in: PubMed
    Score: 0.001
  179. Relationship between surgical-pathological risk factors and outcome in clinical stage I and II carcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol. 1991 Jan; 40(1):55-65.
    View in: PubMed
    Score: 0.001
  180. Running mass closure of abdominal wounds using absorbable looped suture. J Gynecol Surg. 1991; 7(2):107-10.
    View in: PubMed
    Score: 0.001
  181. Prospective surgical-pathological study of disease-free interval in patients with stage IB squamous cell carcinoma of the cervix: a Gynecologic Oncology Group study. Gynecol Oncol. 1990 Sep; 38(3):352-7.
    View in: PubMed
    Score: 0.001
  182. A controlled trial of two low-dose heparin regimens for the prevention of postoperative deep vein thrombosis. Obstet Gynecol. 1990 Apr; 75(4):684-9.
    View in: PubMed
    Score: 0.001
  183. Estrogen and progesterone receptor content of endometrial carcinomas: comparison of total tissue versus cancer component analysis. Gynecol Oncol. 1990 Mar; 36(3):363-8.
    View in: PubMed
    Score: 0.001
  184. Doxorubicin as an adjuvant following surgery and radiation therapy in patients with high-risk endometrial carcinoma, stage I and occult stage II: a Gynecologic Oncology Group Study. Gynecol Oncol. 1990 Feb; 36(2):166-71.
    View in: PubMed
    Score: 0.001
  185. Preoperative serum tumor-associated antigen levels in women with pelvic masses. Obstet Gynecol. 1990 Feb; 75(2):249-54.
    View in: PubMed
    Score: 0.001
  186. A prospective surgical pathological study of stage I squamous carcinoma of the cervix: a Gynecologic Oncology Group Study. Gynecol Oncol. 1989 Dec; 35(3):314-20.
    View in: PubMed
    Score: 0.001
  187. Conservative surgical management of superficially invasive stage I vulvar carcinoma. Gynecol Oncol. 1989 Dec; 35(3):352-7.
    View in: PubMed
    Score: 0.001
  188. Pelvic exenteration: factors associated with major surgical morbidity. Gynecol Oncol. 1989 Oct; 35(1):93-8.
    View in: PubMed
    Score: 0.001
  189. Endometrial cancer: histologic correlates of immunohistochemical localization of progesterone receptor and estrogen receptor. Obstet Gynecol. 1989 May; 73(5 Pt 1):780-5.
    View in: PubMed
    Score: 0.001
  190. Phase II trial of cisplatin as first-line chemotherapy in patients with advanced or recurrent endometrial carcinoma: a Gynecologic Oncology Group Study. Gynecol Oncol. 1989 Apr; 33(1):68-70.
    View in: PubMed
    Score: 0.001
  191. Back and hip pain in pregnancy due to chordoma. Am J Obstet Gynecol. 1967 Dec 15; 99(8):1165-6.
    View in: PubMed
    Score: 0.001
  192. Endometrial adenocarcinoma estrogen receptor content: association of clinicopathologic features with immunohistochemical analysis compared with standard biochemical methods. Am J Obstet Gynecol. 1987 Oct; 157(4 Pt 1):924-31.
    View in: PubMed
    Score: 0.001
  193. Evaluation of the atypical Pap smear. Am J Obstet Gynecol. 1987 Sep; 157(3):544-9.
    View in: PubMed
    Score: 0.001
  194. Histologic composition of endometrial carcinomas analyzed for steroid receptor content. Am J Obstet Gynecol. 1987 Jul; 157(1):26-7.
    View in: PubMed
    Score: 0.001
  195. Immunohistochemical analyses of estrogen receptor in endometrial adenocarcinoma using a monoclonal antibody. Cancer Res. 1986 Oct; 46(10):5419-25.
    View in: PubMed
    Score: 0.001
  196. Prognostic value of peritoneal washings in patients with malignant mixed m?llerian tumors of the uterus. Am J Obstet Gynecol. 1986 Jul; 155(1):83-9.
    View in: PubMed
    Score: 0.001
  197. A randomized trial of cyclophosphamide and doxorubicin with or without cisplatin in advanced ovarian carcinoma. A Gynecologic Oncology Group Study. Cancer. 1986 May 01; 57(9):1725-30.
    View in: PubMed
    Score: 0.001
  198. Estrogen replacement therapy in the patient treated for endometrial cancer. Obstet Gynecol. 1986 Mar; 67(3):326-30.
    View in: PubMed
    Score: 0.001
  199. Absorption of transfused chromium-labeled erythrocytes from the fetal peritoneal cavity in hydrops fetalis. Am J Obstet Gynecol. 1966 Feb 15; 94(4):586-8.
    View in: PubMed
    Score: 0.001
  200. Histologic control of biochemical steroid receptor analysis in endometrial carcinomas. Am J Obstet Gynecol. 1985 Nov 01; 153(5):520-3.
    View in: PubMed
    Score: 0.001
  201. Intraperitoneal chromic phosphate P 32 suspension therapy of malignant peritoneal cytology in endometrial carcinoma. Am J Obstet Gynecol. 1985 Sep 15; 153(2):191-6.
    View in: PubMed
    Score: 0.001
  202. Vincristine, dactinomycin, and cyclophosphamide in the treatment of malignant germ cell tumors of the ovary. A Gynecologic Oncology Group Study (a final report). Cancer. 1985 Jul 15; 56(2):243-8.
    View in: PubMed
    Score: 0.001
  203. Treatment of recurrent or advanced uterine sarcoma. A randomized trial of doxorubicin versus doxorubicin and cyclophosphamide (a phase III trial of the Gynecologic Oncology Group). Cancer. 1985 Apr 15; 55(8):1648-53.
    View in: PubMed
    Score: 0.001
  204. Risk factors and recurrent patterns in Stage I endometrial cancer. Am J Obstet Gynecol. 1985 Apr 15; 151(8):1009-15.
    View in: PubMed
    Score: 0.001
  205. Cytoplasmic estrogen and progesterone receptor content of uterine sarcomas. Am J Obstet Gynecol. 1984 Oct 15; 150(4):342-8.
    View in: PubMed
    Score: 0.001
  206. Induction of cytoplasmic progesterone receptor in human endometrial carcinoma transplanted into nude mice. Am J Obstet Gynecol. 1984 Oct 15; 150(4):437-9.
    View in: PubMed
    Score: 0.001
  207. Survival and patterns of recurrence in cervical cancer metastatic to periaortic lymph nodes (a Gynecologic Oncology Group study). Gynecol Oncol. 1984 Sep; 19(1):8-16.
    View in: PubMed
    Score: 0.001
  208. Perioperative external pneumatic calf compression as thromboembolism prophylaxis in gynecologic oncology: report of a randomized controlled trial. Gynecol Oncol. 1984 Jun; 18(2):226-32.
    View in: PubMed
    Score: 0.001
  209. Surgical staging in endometrial cancer: clinical-pathologic findings of a prospective study. Obstet Gynecol. 1984 Jun; 63(6):825-32.
    View in: PubMed
    Score: 0.001
  210. Phase II clinical study of tamoxifen in advanced endometrial adenocarcinoma: a Gynecologic Oncology Group study. Cancer Treat Rep. 1984 May; 68(5):809-11.
    View in: PubMed
    Score: 0.001
  211. A randomized study of adriamycin with and without dimethyl triazenoimidazole carboxamide in advanced uterine sarcomas. Cancer. 1983 Aug 15; 52(4):626-32.
    View in: PubMed
    Score: 0.001
  212. Phase II study of maytansine in the treatment of advanced or recurrent adenocarcinoma of the ovary. A Gynecologic Oncology Group study. Am J Clin Oncol. 1983 Jun; 6(3):273-5.
    View in: PubMed
    Score: 0.001
  213. Cytopathology and the management of early invasive cancer of the uterine cervix. Obstet Gynecol. 1982 Sep; 60(3):350-3.
    View in: PubMed
    Score: 0.001
  214. Prognostic value of cytologic examination of peritoneal washings in patients with endometrial carcinoma. Acta Cytol. 1981 Nov-Dec; 25(6):640-6.
    View in: PubMed
    Score: 0.000
  215. Risk of exogenous estrogen therapy and endometrial cancer. Am J Obstet Gynecol. 1980 May 01; 137(1):85-91.
    View in: PubMed
    Score: 0.000
  216. Results and complications of operative staging in cervical cancer: experience of the Gynecologic Oncology Group. Gynecol Oncol. 1980 Feb; 9(1):90-8.
    View in: PubMed
    Score: 0.000
  217. Phase II trial of VP-16-213 in the treatment of advanced squamous cell carcinoma of the cervix and adenocarcinoma of the ovary: a Gynecologic Oncology Group Study. Cancer Treat Rep. 1979 Nov-Dec; 63(11-12):2089-92.
    View in: PubMed
    Score: 0.000
  218. Correlation of estrogen and progesterone receptors with histologic differentiation in endometrial adenocarcinoma. Am J Pathol. 1979 Jul; 96(1):171-83.
    View in: PubMed
    Score: 0.000
  219. An alternate approach to early cancer of the vulva. Am J Obstet Gynecol. 1979 Apr 01; 133(7):825-32.
    View in: PubMed
    Score: 0.000
  220. Effects of long-term estrogen replacement therapy. II. Neoplasia. Am J Obstet Gynecol. 1979 Mar 01; 133(5):537-47.
    View in: PubMed
    Score: 0.000
  221. Effects of long-term estrogen replacement therapy. I. Metabolic effects. Am J Obstet Gynecol. 1979 Mar 01; 133(5):525-36.
    View in: PubMed
    Score: 0.000
  222. Endometrial sarcoma: lymphatic spread pattern. Am J Obstet Gynecol. 1978 Jan 01; 130(1):104-5.
    View in: PubMed
    Score: 0.000
  223. Treatment of cervical dysplasia with electrocautery and tetracycline suppositories. Am J Obstet Gynecol. 1973 Oct 15; 117(4):460-3.
    View in: PubMed
    Score: 0.000
  224. Treatment of metastatic trophoblastic disease: good and poor prognosis. Am J Obstet Gynecol. 1973 Feb 15; 115(4):451-7.
    View in: PubMed
    Score: 0.000
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.